CA2184631A1 - Produit et procede de regulation des voies de transduction de signaux - Google Patents

Produit et procede de regulation des voies de transduction de signaux

Info

Publication number
CA2184631A1
CA2184631A1 CA002184631A CA2184631A CA2184631A1 CA 2184631 A1 CA2184631 A1 CA 2184631A1 CA 002184631 A CA002184631 A CA 002184631A CA 2184631 A CA2184631 A CA 2184631A CA 2184631 A1 CA2184631 A1 CA 2184631A1
Authority
CA
Canada
Prior art keywords
peptide
motif
amino acid
kinase
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002184631A
Other languages
English (en)
Inventor
John C. Cambier
Christopher M. Pleiman
Marcus R. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2184631A1 publication Critical patent/CA2184631A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des produits et des procédés de régulation de voies de transduction de signaux dans des cellules. L'invention se rapporte d'une part, à un peptide présentant un motif aminoacide YXXLXXXXXXXYXX? et utile dans la régulation de l'activité des tyrosine-kinases, des lipide-kinases et des molécules d'adaptation. Elle porte, d'autre part, sur un produit et un procédé d'inhibition de voies de transduction de signaux dans des cellules impliquant un peptide capable de se lier au domaine SH3 d'une tyrosine-kinase, pour bloquer ainsi la liaison et l'activation d'un effecteur par la tyrosine-kinase. Le composé et la composition peptidique peuvent être utilisés dans le traitement de troubles médicaux tels que les réactions allergiques, les maladies auto-immunes, les réactions inflammatoires, le cancer, les déficiences immunitaires, les maladies immunoprolifératives et celles dues à des virus tels que le virus Epstein-Barr et le virus de la leucémie bovine.
CA002184631A 1994-03-17 1995-03-17 Produit et procede de regulation des voies de transduction de signaux Abandoned CA2184631A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21511694A 1994-03-17 1994-03-17
US215,116 1994-03-17

Publications (1)

Publication Number Publication Date
CA2184631A1 true CA2184631A1 (fr) 1995-09-21

Family

ID=22801724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002184631A Abandoned CA2184631A1 (fr) 1994-03-17 1995-03-17 Produit et procede de regulation des voies de transduction de signaux

Country Status (4)

Country Link
EP (1) EP0804218A1 (fr)
JP (1) JPH09512704A (fr)
CA (1) CA2184631A1 (fr)
WO (1) WO1995024915A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976819A (en) * 1995-11-21 1999-11-02 National Jewish Medical And Research Center Product and process to regulate actin polymerization in T lymphocytes
WO1998017323A1 (fr) * 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Vaccins perfectionnes
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CA2364160C (fr) 1999-02-25 2014-05-20 National Jewish Medical And Research Center Produit et methode de traitement de maladies associees a la desensibilisation de recepteurs
WO2003006060A1 (fr) * 2001-07-09 2003-01-23 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de la liaison au domaine sh3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667803B2 (en) * 1991-01-18 1996-04-18 New York University A receptor tyrosine kinase target protein cDNA cloning method and hGRB proteins
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
AU6098194A (en) * 1993-01-29 1994-08-15 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
WO1994018832A1 (fr) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Modulation a mediation cd4 de kinases lipidiques
CA2142713A1 (fr) * 1993-06-30 1995-01-12 Paolo Comoglio Inhibiteurs peptidiques de la mitose et de la motogenese
DE69534920T2 (de) * 1994-07-22 2007-04-05 University Of North Carolina Src SH3 BINDENDE PEPTIDE UND VERFAHREN ZU IHRER ISOLIERUNG UND VERWENDUNG
CA2247207A1 (fr) * 1995-02-28 1996-09-06 National Jewish Center For Immunology And Respiratory Medicine Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation
US7815749B2 (en) * 2006-06-29 2010-10-19 Hitachi Metals, Ltd. Method for manufacturing semi-hard magnetic material and semi-hard magnetic material

Also Published As

Publication number Publication date
AU2187495A (en) 1995-10-03
AU699662B2 (en) 1998-12-10
WO1995024915A1 (fr) 1995-09-21
EP0804218A1 (fr) 1997-11-05
JPH09512704A (ja) 1997-12-22
EP0804218A4 (fr) 1997-11-12

Similar Documents

Publication Publication Date Title
Matsuoka et al. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase
Johnson et al. Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases
Garton et al. Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition
CA2256483C (fr) Lipide kinase p13
Sotirellis et al. Autophosphorylation induces autoactivation and a decrease in the Src homology 2 domain accessibility of the Lyn protein kinase
Stahelin et al. Protein kinase Cθ C2 domain is a phosphotyrosine binding module that plays a key role in its activation
Piwnica-Worms et al. Regulation of pp60c-src and its interaction with polyomavirus middle T antigen in insect cells
CA2609633C (fr) Compositions de nicotinamide riboside
WO1994024159A1 (fr) Procede et produit de regulation de la reactivite cellulaire a des signaux externes
US5744313A (en) Assay employing novel protein domain which binds tyrosine phosphorylated proteins
JP2000500964A (ja) 細胞シグナリングのモジュレーターを同定する方法
Bjorge et al. Characterization of Two Activated Mutants of Human pp60c-src That Escape c-Src Kinase Regulation by Distinct Mechanisms (∗)
JP4603240B2 (ja) ＮＦ−κＢ活性化受容体のインヒビターおよびその使用
US6296848B1 (en) GRB2 associating polypeptides and nucleic acids encoding therefor
EP0804218A1 (fr) Produit et procede de regulation des voies de transduction de signaux
WO1997019101A9 (fr) Nouveaux polypeptides s'associant a la proteine grb2 et acides nucleiques les codant
AU699662C (en) Product and process for regulating signal transduction pathways
WO1995026983A2 (fr) Traitement ou diagnostic de troubles caracterises par des anomalies de la transduction de signaux
JP3471879B2 (ja) セリンキナーゼ活性の抑制方法、ｐｉ３−キナーゼのサブユニット間の結合活性の調整方法、ｐｉ３−キナーゼのサブユニット結合抗体、この抗体を生成するハイブリドーマ細胞系、核酸分子、プラスミド、アゴニスト、アンタゴニスト、ｐｉ３−キナーゼ活性を抑制するサブユニット結合分子、サブユニットの存在検出方法、ｐｉ３−キナーゼ活性の抑制剤製造方法、およびｐｉ３−キナーゼ活性の抑制剤
US6531296B1 (en) Nuclear tyrosine kinase Rak
Turner Signal transduction by the high affinity receptor for immunoglobulin E, FcϵRI, in the mast cell line RBL-2H3
Turner Signal transduction by the high affinity receptor for immunoglobulin E, FcepsilonRI, in the mast cell line RBL-2H3
WO1997020573A1 (fr) Homologue de proteine 2 se liant au recepteur du facteur de croissance
Lue Molecular and biomechanical characterization ofhdlg: The human homologue of the Drosophila discs-large tumor suppressor protein
JP2001503994A (ja) チロシンリン酸化切断溝関連タンパク質（ｐｓｔｐｉｐ）

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued